Vedanta Biosciences
Vedanta is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria.
$60M ·
Source: fundraisingfox.com
Total raised: $166.5M across 2 sourced rounds
All 3 rounds ↓Signals
X account@VedantaBio · created Dec 17, 2015 (10 years old) · 1,624 followers
Website registeredAug 25, 2010 (16 years old)
TIMELINE · MONEY RAISED
Vedanta Biosciences | 2043 days from X account to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Round | $60M | — | fundraisingfox.com | |
| Series B+ | $106.5M | pulse2.com | ||
| Series B+ | undisclosed | vedantabio.com |
Timeline
- X account created
- Website created
Founders and team
BO
Bernat Olle 🇺🇦 Founder & CEO@bernatolle · source: x.comAR
Alexander Rudensky FounderDL
DS
David Steinberg FounderRM
Ruslan Medzhitov FounderSC
Silvia Caballero Director, Infectious DiseasesDC
Daniel Couto Chief Operating OfficerJS
Jeffrey Silber CMOSL
Simona Levi Chief Legal Officer
Investors
AAMR Action Fundlead investor
- AAtlantic Neptune
AAXA Investment Managerslead investor
BBNP Paribas Asset Management
CCARB-X
CColorcon Ventures
- FFiscus Ventures
- HHealth for Life Capital fund
- JJSR
KKorea Investment & Securities
MMagnetar Capitallead investor
PPeak 6
PPfizer Venture Investments
PPureTech Health
- QQUAD Investment Management
RReimagined Ventures
RRevelation Partners
RRock Springs Capital
SSalica
SSeventure Partners
SShumway CapitalSSkyviews Life Science
SSymBiosis
- VVerition Fund Management
Companies like Vedanta Biosciences
DDiadem Biotherapeutics
LLassen Therapeutics$85M Series B+ · Jan 2024
CCamp4Series B+ · Jul 2022
VVandria$30.7M Series A · Aug 2024LLucina BiotherapeuticsSeed · Aug 2026
EEstuary Biotherapeutics$103M Series A · Oct 2026
Other companies backed by AMR Action Fund
PPeptilogics$78M Series B+ · Oct 2025
FF2G$100M Series B+ · Sep 2024
AAdaptive Phage Therapeutics$24M Series B+ · Jun 2023
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/vedanta-biosciences (get a free API key).